A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
DRUG: GFH009
Phase Ib: adverse events, Incidence of intolerable toxic events, incidence and severity of adverse events (AEs) and serious adverse events (SAEs), From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)|Phase II: Objective Response Rate, ORR(Objective Response Rate), From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma